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Background: TAS-102 is an oral monotherapy, combining 
trifluridine and tipiracil hydrochloride, indicated for the treatment 
of pretreated metastatic colorectal cancer (mCRC). The aim of this 
real-life study is to evaluate the efficacy and safety of TAS-102 in 
heavily pretreated elderly patients with mCRC whose disease has 
progressed with standard therapies.
Methods: In this retrospective observational study, we enrolled 
50 elderly patients >70 years of age (median age 78 years) with 
a diagnosis of mCRC who were previously treated or were 
not considered candidates for treatment with other available 
therapies. Patients aged >70 years with advanced colorectal cancer 
and with an ECOG performance status of grade 0 (n=18) or grade 1  
(n=32) were included. Overall survival and progression-free 
survival were the primary endpoints, whereas objective response 
rate, tolerability, and quality of life were the secondary endpoints. 
Results: Treatment with TAS-102 appeared to be well tolerated 
and side effects were generally mild, achieving disease control 
and a benefit on quality of life. The median overall survival was 
6.7 (95% CI 5.7–11.3) and the median progression-free survival 
was 2.1 months (95% CI 1.2–3.2), estimated using the Kaplan–
Meier method. 
Conclusion: TAS-102 represents a manageable and 
effective therapeutic opportunity and appeared to be well 
tolerated with generally mild side effects in elderly patients 
with mCRC who were heavily pretreated with standard 
therapies. 
Keywords: chemotherapy, elderly patients, Lonsurf, metastatic 
colorectal cancer, quality of life, TAS-102, trifluridine/ 
tipiracil.
Citation
Cicero G, Addeo R, De Luca R, Lo Re G, Gulotta L, Marchesa P, 
Gaspare G. TAS-102 in elderly patients with mCRC: a  
real-world study. Drugs in Context 2020; 9: 2020-6-3.  
DOI: 10.7573/dic.2020-6-3
Giuseppe Cicero MD PhD1, Raffaele Addeo MD2, Rossella De Luca PhD1, Giuseppe Lo Re MD PhD3, Leonardo Gulotta MD4, 
Pierenrico Marchesa MD5, Gaspare Gulotta MD PhD4
1Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy; 2Oncology 
Unit, ASLNapoli2NORD, Frattamaggiore (Na), Italy; 3Department of Radiology, University of Palermo, Palermo, Italy; 4Department 
of Surgical, Oncological and Oral Sciences, Section of General and Emergency Surgery, University of Palermo, Palermo, Italy; 
5ARNAS Hospital Civico, Di Cristina, Benfratelli, Surgical Oncology Unit, Palermo, Italy
TAS-102 in metastatic colorectal cancer (mCRC): efficacy, tolerability, and quality of 
life in heavily pretreated elderly patients: a real-life study
ACCESS ONLINE
Introduction
Colorectal cancer (CRC) represents the second most common 
malignancy by incidence in western countries after breast 
cancer in women and prostate cancer in men. Although 
the prognosis linked to CRC has improved in recent years, 
mortality remains high, especially for refractory or metastatic 
CRC (mCRC). Indeed, mCRC is a major cause of death from 
malignant neoplasm.1 Approximately 20% of patients with CRC 
have clinically detectable liver metastases at initial diagnosis 
and approximately 45% develop metastases during the course 
of the disease.2,3 A multidisciplinary group approach represents 
the best path for the correct management of patients with 
mCRC. The introduction of new drugs into clinical practice has 
progressively improved survival in advanced disease, bringing 
the median survival to 24 months; furthermore, in some cases, 
new drugs have allowed the conversion of advanced disease 
from unresectable to surgically resectable.4, 5 
In heavily pretreated patients and in elderly patients >70 years 
of age, the goal of systemic treatment is to improve quality 
of life (QoL), prolong survival, and to postpone the onset of 
complications related to the disease. TAS-102 (Lonsurf®) is an 
oral monotherapy that combines trifluridine (FTD) and tipiracil 
hydrochloride (a thymidine phosphorylase inhibitor) and is 
indicated for the treatment of mCRC in heavily pretreated 
patients.6 FTD acts by incorporation into DNA, resulting in cell 
cycle arrest and cell death,7 whereas tipiracil hydrochloride 
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maintains adequate plasma concentrations of FTD by inhibiting 
thymidine phosphorylase, which degrades FTD.5 In the phase 
III RECOURSE study, TAS-102 demonstrated an improvement in 
overall survival (OS) from 5.3 to 7.1 months and in progression-
free survival (PFS) from 1.7 to 2.0 months, without significant 
adverse effects and with a good safety profile in heavily 
pretreated patients.8 Furthermore, an analysis of the subgroups 
of the RECOURSE study highlighted the benefits of TAS-102 
treatment in elderly patients.9 Age does not affect the efficacy 
of TAS-102 and does not represent a potential risk factor for 
toxicity. Therefore, age alone should not preclude the use of 
TAS-102 in patients aged >70 years.10, 11 However, despite the 
high incidence of this disease in elderly patients, the available 
clinical practice information regarding this population is 
limited and incomplete. Based on the results of the RECOURSE 
subgroups as well as on studies by Van Cutsem et al.8 and 
others,9,12,13 we conducted a study to evaluate the safety and 




This observational retrospective study was conducted to 
evaluate the safety and efficacy of TAS-102 monotherapy in 
mCRC in elderly patients treated at the Oncology Unit of the 
University of Palermo. The patients enrolled in this study had 
previously been treated with or were refractory to standard 
therapies, including oxaliplatin, irinotecan, 5-fluorouracil, 
capecitabine, anti-VEGF drugs, and anti-EGFR drugs. No 
patients had previously been treated with regorafenib. OS and 
PFS were the primary endpoints, whereas objective response 
rate (ORR), tolerability, and QoL were the secondary endpoints. 
The study was approved by the Ethics Committee of Policlinic 
Palermo, Italy, in the January 2014 session. Consent from the 
patients was obtained to review their medical records. The 
study was conducted in accordance with the provisions of the 
Declaration of Helsinki and good clinical practice guidelines 
and all patients enrolled provided written informed consent 
to be treated with TAS, for data storage, and for future analysis 
and publication of the data.
Patient selection
This retrospective observational study was conducted between 
March 2014 and June 2019 and involved the treatment of a 
total of 50 patients aged >70 years and with a mCRC diagnosis 
refractory or intolerant to standard therapies; all patients 
were treated with TAS-102 (see Modality of administration 
section) in our Institution. All patients were judged not to 
be amenable to regorafenib treatment due to poor clinical 
conditions. To be eligible for inclusion, all patients must have 
received approved conventional therapies and documented 
disease progression. Furthermore, all patients evaluated 
had to meet the following inclusion criteria: (1) colorectal 
carcinoma, histologically or cytologically confirmed, with 
measurable or evaluable disease; (2) unresectable stage IV 
carcinoma pretreated with conventional therapies; (3) age 
over 70 years; (4) life expectancy >3 months; (5) regular cardiac 
function with left ventricular ejection fraction at rest >50% 
and sinus rhythm on the electrocardiogram; (6) performance 
score status between grades 0 and 1 according to the Eastern 
Cooperative Oncology Group (ECOG); (7) clinical or radiological 
evidence of metastatic measurable disease by spiral computer 
tomography (CT) scan or magnetic resonance imaging scan, in 
accordance with Response Evaluation Criteria In Solid Tumors 
(RECIST) version 1.1, with ≥1 lesions; and (8) the required 
laboratory results (neutrophils 2.0×109/L, platelets 100×109/L, 
hemoglobin 10 g/dL, creatinine 1 mg/dL, the upper limit of the 
standard (ULN), creatinine clearance >60 mL/min if creatinine 
was above the indicated limit, bilirubin 1×ULN, aspartate 
aminotransferase and alanine aminotransaminase 5×ULN, 
and alkaline phosphatase 5×ULN; except in the presence of 
bone metastases). Patients with asymptomatic central nervous 
system metastases were included in the study provided that 
surgical or radiotherapy treatment was completed no more 
than 3 months prior. Patients were excluded from the study 
if they (1) were hypersensitive to TAS-102 and its excipients or 
other components of the formulation; (2) had a diagnosis of 
other malignant tumors except for adequately treated basal 
cell carcinoma of the skin; (3) had clinically active cardiovascular 
disease, myocardial infarction in the 6 months prior to 
enrollment in the study, or severe cardiac arrhythmia; (4) had 
symptomatic brain metastases; or (5) had severe comorbidity 
not adequately controlled by other ongoing therapies (liver 
disease, diabetes, infections, heart disease, etc.).
Evaluation of response and toxicity
The evaluation of response rate in terms of measurable 
pathology reduction, in accordance with RECIST version 1.1,14 
was conducted at the beginning of treatment and every 3 
months until disease progression. A spiral CT scan was always 
performed before the start of treatment and subsequently 
on average every 3 months or coinciding with the alleged 
progression. Positron emission tomography was performed 
in selected cases at the discretion of the physician. In the 
case of brain metastases, a magnetic resonance imaging scan 
was performed every 6–12 weeks. Dose interruptions were 
authorized to manage treatment-related adverse events. Basic 
laboratory assessments were always performed every 12–14 
days and before the next treatment, and safety assessments 
were made during the treatment phase. Management of 
hematological toxicity in elderly patients treated with TAS-102 
resulted in discontinuation of dosing until the toxicity was 
resolved by returning the values to at least G1 or baseline. 
The drug-related toxicities were classified according to the 
Common Terminology Criteria for Adverse Events (CTCAE) 
version 4.0. Treatment continued until clinical benefit was 
observed or until treatment was no longer tolerated.
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QoL value 
QoL was routinely assessed for all patients at the start of 
treatment and at the first follow-up (3 months) through the 
administration of the EORTC QLQ-C30 (European Organization 
for Research and Treatment of Cancer)15 questionnaire by a 
psycho-oncologist; EORTC QLQ-C30 is composed of both 
multiitem scales and single-item measures, including five 
functional scales (physical, role, cognitive, emotional, and 
social), three symptom scales (fatigue, pain, and nausea and 
vomiting), a global health status/QoL scale, and six single items 
(dyspnea, loss of appetite, insomnia, constipation, diarrhea, and 
perceived financial impact of the disease). A higher scale score 
represents a higher response level. Thus, a high score for a 
functional scale represents a high/healthy level of functioning, 
a high score for global health status/QoL represents a high QoL, 
but a high score for a symptom scale/item represents a high 
level of symptomatology/problems.
Modality of administration
Considering a 28-day cycle, TAS-102 was administered orally 
twice a day for 5 days, followed by a 2-day break, repeated 
for 2 weeks, with a subsequent 14-day break period. The 
recommended starting dose was 35 mg/m2, administered 
orally twice daily and doses not taken, either because 
they were forgotten or suspended, did not have to be 
compensated. Dose reductions were anticipated (up to a 
maximum of three reductions) in case of additional toxicity. 
Before resuming treatment, the dose had to be reduced by 5 
mg/m2 compared to the previous dosage. These reductions 
were allowed up to a minimum dose of 20 mg/m2 twice daily. 
Adherence was assessed using the medication possession ratio 
and the proportion of days covered at 3 months. In addition, 
during the entire treatment period, the patient was advised to 
maintain adequate hydration to prevent complications such as 
kidney failure. Treatment was administered until progression, 
unacceptable toxicity, or patient rejection. According to  
clinical practice procedures, therapy was postponed for  
up to 2 weeks if the neutrophil count was <1.5×109/L or if 
the platelet count was <100×109/L, if the hemoglobin level 
was <8.5 g/dl, or if bilirubin and/or transaminase levels were 
>1.5×ULN. In the case of neutropenia (grade 2–3) granulocyte 
colony-stimulating factor (G-CSF) was subcutaneously 
administered as prophylaxis. In case of severe anemia  
(grade 4), blood transfusions were performed, whereas 
erythropoietin ampoules were administered subcutaneously  
in less severe cases. Finally, platelet infusions were 
administered intravenously in cases of severe 
thrombocytopenia (grade 4). Progressing patients were 
assigned to begin a new treatment.
Statistical analysis
The analyses were performed using statistical software SPSS 
(Statistical Package for Social Science) version 25.0 for Mac 
(IBM Corp.). Descriptive statistical analysis was performed to 
provide a sociodemographic representation of the group of 
participants in the study and to explore how the analyzed 
variables were distributed. The normality of distribution was 
verified through univariate kurtosis and asymmetry indices 
with an acceptance threshold of 1. No variance violated 
the normality indices. Inferential statistical analyses were 
performed to detect the existence of significant associations 
between the variables considered. The disease control rate 
was defined as the percentage of patients with an objective 
response and/or stable disease lasting >6 months. PFS and OS 
were calculated from the date of the beginning of treatment 
until the date of disease progression or death from any cause 
for PFS and until the date of the last follow-up, death, or final 
follow-up day of evaluation for OS. PFS and OS curves were 
estimated using the Kaplan–Meier method. The last follow-
up was in December 2019. In addition, the Bravais–Pearson 
(r) linear correlation index was used to measure the intensity 
of the bond between the OS variable and QoL with a 95% 
confidence interval (CI). Considering the sample amplitude, 
parametric statistics were used and a threshold value of 




The retrospective analysis was performed by including 50 
nonconsecutive patients (28 men and 22 women), with an 
average age of 78 years (range 70–86). All patients underwent 
primary tumor surgery, and all patients had previously 
undergone conventional therapies such as oxaliplatin, 
irinotecan, 5-fluorouracil, capecitabine, anti-VEGF, and 
anti-EGFR in patients with wild-type RAS, but none had any 
prior treatment with regorafenib. Following biomolecular 
investigations, 32 patients were shown to have mutant 
KRAS tumors and 18 patients had wild-type KRAS. Only 12 
patients were evaluated for BRAF status. A total of 18 patients 
had an ECOG performance status of grade 0 and 32 had an 
ECOG performance status of grade 1. Patients with an ECOG 
performance status of grade 2 were excluded from the study. 
The sites of disease at the last radiological investigation were 
the liver, lungs, and peritoneum (Table 1). Heart failure or 
left ventricular ejection fraction did not occur in any patient. 
During the study period, in our center, 52 patients were 
treated with regorafenib whereas 32 received supportive 
therapy alone.
OS and PFS analysis 
Among the 50 patients enrolled in this study, the updated 
interim analysis of survival showed a median OS of 6.7 months 
(95% CI 5.7–11.3) (Figure 1). Median PFS was 2.1 months (95% CI 
1.2–3.2) (Figure 2).
Cicero G, Addeo R, De Luca R, et al. Drugs in Context 2020; 9: 2020-6-3. DOI: 10.7573/dic.2020-6-3 4 of 8
ISSN: 1740-4398
ORIGINAL RESEARCH – TAS-102 in elderly patients with mCRC: a real-world study drugsincontext.com
ORR analysis
Treatment with TAS-102 showed a good level of disease control 
with a manageable toxicity profile. No partial or complete 
responses were reported (ORR 0%). The first instrumental 
re-evaluation with spiral CT was performed after 3 months of 
treatment. Two patients did not undergo disease reassessment: 
one patient died after the first cycle and one patient was soon 
lost to follow-up due to complications. The overall ORR was 0%, 
disease stabilization 58%, disease progression was 38%, and 
4% were not evaluable (Table 2). The mean duration of follow-
up was of 6.1 months (range 3–9.2 months), and the median 
response time was 9.2 weeks (95% CI 6.7–12.2 weeks) with a 
significant impact on the QoL. The bimolecular evaluation of 
tumor mutation status compared to KRAS showed that the 
benefits of TAS-102 treatment were observed in both tumor 
mutation patient subgroups without statistical differences. 
In the 18 patients with a BRAF mutational status, TAS-102 
also showed a benefit. The treatment showed a good level of 
disease control with no objective response; therefore, TAS-102 
was associated with stable disease with a manageable toxicity 
profile in heavily pretreated elderly patients with mCRC.
QoL analysis
QoL was measured with EORTC QOL-C30 (ref.15) and was 
analyzed as a change from baseline at follow-up with a score 
of 49.6 (0–100) in the global health status/QoL scales. The QoL 
showed an improvement with treatment in 58% of patients. 
Scores on the functional scales of the EORTC QLQ-C30 varied, 
indicating that the patients’ QoL was sufficient overall. An 
improvement in QoL was also identified with a reduction in 
pain symptoms, with a score of 33.5, and an improvement in 
physical functioning (score 39.6), role functioning (score 42.4), 
constipation (score 23.6), fatigue (score 24.1), and appetite 





















95% CI: 5.7–11.3 mOS 6.7





















95% CI: 1.2–3.2 mOS 2.1
Table 1. Baseline demographic and clinical 
characteristics (n=50).
Characteristics Patients, % (n)








Single left site 48% (24)
Single right site 24% (12)
Single transverse site 8% (4)
Single rectum site 20% (10)
KRAS status
Wild type 28% (14)
Mutated 52% (26)
BRAF status





Peritoneum 52% (26) 
Other 12% (6)
ECOG, Eastern Cooperative Oncology Group.
Cicero G, Addeo R, De Luca R, et al. Drugs in Context 2020; 9: 2020-6-3. DOI: 10.7573/dic.2020-6-3 5 of 8
ISSN: 1740-4398
ORIGINAL RESEARCH – TAS-102 in elderly patients with mCRC: a real-world study drugsincontext.com
30 mg/m2 bid and the patients continued without significant 
disturbances and good hematological tolerance. Other 
common adverse events included fatigue (6%), grade 3 nausea 
(6%), vomiting (6%), diarrhea (4%), hand–foot syndrome (4%), 
and hyperbilirubinemia (2%) (Table 3). All adverse events were 
managed, generally on an outpatient basis, with adequate 
intervention of supportive therapies and with a reduction 
or postponing of subsequent administration in line with the 
TAS-102 guidelines. Dose reduction and dose interruptions 
were authorized to manage treatment-related adverse events. 
The dose was reduced in three patients due to toxicity yet it 
was not postponed in any patient. Four patients underwent 
thermal ablation on liver metastases. Treatment continued until 
clinical benefit was observed or until treatment was no longer 
tolerated.
Discussion
The incidence of tumors increases significantly with age, with 
a subsequent increase in the incidence of CRC in the elderly. 
In 2019, 24% of newly diagnosed CRC patients were aged 
>70 years16 and 14% of CRC deaths are expected to occur in 
these patients in the coming years.17,18 In elderly patients 
with mCRC, the goal of treatment includes the control of 
symptoms, maintaining good QoL, and increasing survival. 
Despite the rapid growth in the number of onco-geriatric 
patients, elderly cancer patients are underrepresented  
in clinical trials and the results of clinical trials in younger 
patients cannot be extrapolated to the treatment of the 
Table 2. Overall response rate (n=50).







Overall response rate (CR+PR) (0)
Clinical benefit rate (CR+PR+SD) (52)
CR, complete response; PR, partial response; SD, stable 
response.
loss (score 23.1). Moreover, the Bravais–Pearson index showed 
a positive correlation between the response rate of OS and 
QoL, with a value of 0.58 (95% CI 0.24–0.79; p=0.006). The 
compliance with TAS-102 treatment was assessed by a monthly 
telephone interview with patients and at least one of their 
family members by a psycho-oncologist.
Safety and adverse events
A total of 380 therapy cycles were performed, with each patient 
undergoing 7.6 cycles on average. The duration of treatment 
in one patient reached 14 months. Treatment-related toxicity 
was well tolerated and adverse events were assessed after each 
cycle of therapy and reported in line with CTCAE version 4.0. 
No patient died from treatment-related adverse events. Most 
adverse reactions related to TAS-102 therapy were resolved 
with the application of established safety guidelines. The 
hematological toxicity was the most frequent complication; 
13 (26%) patients developed grade 3–4 neutropenia, which 
required the use of G-CSF as prophylaxis; 8 (16%) patients 
developed febrile neutropenia, which required the use of 
antibiotics and G-CSF; 2 (4%) patients developed grade 2 
thrombocytopenia, which required the use of corticosteroids; 
and 4 (8%) patients developed grade 3 anemia, which required 
the administration of subcutaneous erythropoietin. All toxicity 
effects were managed by dose modification and delayed 
administration. Due to deteriorating clinical conditions, 
advanced age, and comorbidities, one patient stopped 
treatment after three administrations. An episode of grade 4 
febrile neutropenia occurred in three patients at the end of 
the first cycle on day 27, which caused a delay of 6 days at the 
beginning of the second cycle and was treated with antibiotic 
therapy and subcutaneous G-CSF as prophylaxis. Treatment 
continued without a dose reduction. During the fourth cycle, 
two other patients experienced a febrile episode of grade 
4 neutropenia that caused treatment to stop for 8 days and 
prophylaxis with subcutaneous G-CSG was administered with 
blood chemistry monitoring. Considering the suspension of 
therapy for more than a week, the dose was reduced to  
Table 3. Adverse events graded according CTCAE, 
Version 4.0 (n=50).





Anemia 18% (9) 8% (4)
Neutropenia 36% (18) 26% (13)
Thrombocytopenia 4% (2) 0% (–)
Febrile neutropenia 16% (8) 16% (8)
Nonhematological
Nausea 16% (8) 0% (–)
Vomiting 8% (4) 2% (1)
Constipation 0% (–) 0% (–)
Fatigue 18% (9) 4% (2)
Hyperbilirubinemia 8% (4) 2% (1)
Hand–foot syndrome 10% (5) 4% (2)
Peripheral neuropathy 0% (–) 0% (–)
Diarrhea 12% (6) 2% (1)
CTCAE, Common Terminology Criteria for Adverse 
Events.
Cicero G, Addeo R, De Luca R, et al. Drugs in Context 2020; 9: 2020-6-3. DOI: 10.7573/dic.2020-6-3 6 of 8
ISSN: 1740-4398
ORIGINAL RESEARCH – TAS-102 in elderly patients with mCRC: a real-world study drugsincontext.com
elderly. Indeed, the effects of drug toxicity on older people 
are different than in younger patients. While the adverse 
events of grade 2 are not important in young people and  
are often not reported, the same level of toxicity can lead  
to a significant deterioration of functionality in elderly 
patients. In this real-life study, we demonstrated that TAS-102 
has definite activity with a manageable toxicity profile in  
elderly patients with mCRC refractory to standard 
chemotherapy. In our study, TAS-102 demonstrated a median 
OS of 6.7 months and a median PFS of 2.1 months, in line  
with reported data.19,20 Our data confirm previous results that 
show that treatment with FTD/tipiracil in daily clinical practice 
is feasible and safe. In an analysis carried out on 136 patients 
from different Dutch centers, TAS-102 treatment achieved 
median PFS and median OS of 2.1 (95% CI 1.8–2.3) and 5.4 
months (95% CI, 4.0–6.9), respectively.21 Cardiotoxicity in the 
form of cardiac arrhythmia, myocardial infarction, and angina-
like symptoms or common complications of fluoropyrimidines 
(such as 5-fluorouracil and capecitabine) did not occur in any 
patient in this study. TAS-102 is a drug of choice for heavily 
pretreated elderly patients with advanced CRC who suffer 
from heart problems during treatment with 5-fluorouracil or 
capecitabine.22 Moreover, it appears to be the most available 
cardio-delicate nucleoside analog in clinical practice and 
may represent the preferred agent when 5-fluorouracil is 
indicated.23 These results reveal that elderly patients can 
tolerate TAS-102 as well as young patients without frequent 
interruptions due to adverse events.24,25 The advantage was 
evident regardless of the presence or absence of mutations in 
KRAS and BRAF. 
The elderly patient with cancer is often excluded from 
clinical studies, making them particularly exposed to the 
risk of adverse reactions and drug interactions due to their 
reduced functionality of organs and systems.26,27 Another 
very important aspect in clinical studies with elderly 
patients with cancer is the geriatric assessment, including 
not only the age but also the functional, social, and mental 
state of patients. A comprehensive geriatric assessment 
leads to improved assessment and better determines the 
individual treatment strategies for optimal outcome. Herein, 
a comprehensive geriatric assessment was performed in all 
but 12 patients because an expert geriatrician is not available 
in our healthcare facility. We assessed cognitive and social 
function with the administration of the QoL questionnaire by 
the psycho-oncologist. The psycho-oncologist also assessed 
treatment compliance and 90% of patients reported taking 
the drugs as prescribed by the investigator except in the 
event of interruptions due to toxicity. The collaboration of 
family members was fundamental in the management of 
these patients, as shown by the medication possession ratio 
and proportion of days covered at 3 months. This real-life 
analysis suggests that TAS-102 monotherapy has a promising 
activity with manageable safety, suggesting that it could be a 
potential treatment option for heavily pretreated or refractory 
elderly patients with all standard therapies in mCRC, 
according to previous clinical practice studies.28 
The adverse events among elderly patients in this study 
were no different from those in younger patients from other 
studies. Therefore, the therapeutic approach with TAS-102 
for heavily pretreated elderly patients with mCRC recalls 
that of younger patients. Thus, this study suggests that 
oral monotherapy with TAS-102 can represent one of the 
emerging therapeutic options in mCRC in pretreated elderly 
patients aged >70 years, with a favorable risk-to-benefit 
ratio.26,29 The results show that TAS-102 is well tolerated and 
safe in heavily pretreated elderly patients and confirmed that 
the main benefit is associated with stable disease rather than 
with tumor reduction, even considering that the objective 
response to treatment was only observed in a few patients. 
In addition, an increase in survival curves was also observed. 
TAS-102 is effective and safe regardless of the status of KRAS 
and BRAF. Furthermore, a significant correlation between QoL 
and OS was also observed.
Conclusion
The present observational analysis on heavily pretreated 
elderly patients with mCRC confirms that, in clinical daily 
practice, TAS-102 achieved a prolongation of OS and PFS7,8 
with a clinical benefit that continued until toxicity or disease 
progression. TAS-102 was shown to have a manageable safety 
profile with a favorable impact on toxicity management as 
determined by on QoL assessment. The effects of population 
aging and the increased diagnosis of cancer in the elderly 
will require greater coordination between oncologists and 
geriatricians to identify which older adults might be able to 
undergo the various systemic treatments available; for this 
aim, a complete geriatric assessment is helpful. Furthermore, 
an analysis of the subgroup of the appeal study 9,11 did not 
indicate age as a potential factor of increased toxicity or 
decreased efficacy of TAS-102. Thus, TAS-102 was shown to 
have a definite clinical activity in a population of patients 
widely pretreated for mCRC, including those whose disease 
was refractory to fluorouracil and in all patient subgroups. 
This study demonstrates how treatment with TAS-102 may 
represent a valid therapeutic alternative with manageable 
and relatively contained toxicity in heavily pretreated elderly 
patients.
Limitations of the study
The limitations of this analysis include the limited number and 
the nonrandom sampling of patients. However, bearing in 
mind the retrospective nature of the analysis and the limited 
number of patients in a single institution, our results yield valid 
hypotheses for future studies, which should nevertheless be 
confirmed and validated with prospective randomized trials 
focused on elderly patients.
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